Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1414 | Ergoferon Wiki | 1.00 |
| drug4205 | VenaSeal™ Closure System Wiki | 1.00 |
| drug3824 | Surgical Stripping Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014777 | Virus Diseases NIH | 0.11 |
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease
Description: Peri-procedural patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQe).
Measure: Venous treatment satisfaction questionnaire-early (VenousTSQe)(For Randomized studies, VenaSeal vs. ETA and VenaSeal vs. Surgical Stripping Study) Time: 30 daysDescription: Patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQs).
Measure: Venous treatment satisfaction questionnaire- status (VenousTSQs) (For Randomized studies, VenaSeal vs. ETA and VenaSeal vs. Surgical Stripping Study) Time: 30 daysDescription: Elimination of clinically relevant superficial truncal disease in each target vein at the time of index procedure as measured by the percentage of target vein length successfully treated.
Measure: Percentage of target vein treated (For Randomized studies, VenaSeal vs. ETA and VenaSeal vs. Surgical Stripping Study) Time: Index procedureDescription: Time to ulcer healing, calculated through healing confirmation and verified by an independent core laboratory.
Measure: Time to ulcer healing (For VLU study) Time: Index procedure through 24 monthsDescription: Measured via Duplex Ultrasound showing primary target vein closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual primary target vein after surgical stripping procedures.
Measure: Anatomic closure of the primary target superficial truncal vein Time: 6 monthsDescription: Measured via Duplex Ultrasound showing primary target vein closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual primary target vein after surgical stripping procedures.
Measure: Anatomic closure of primary target vein Time: 30 days, and 12, 24, 36, 48 and 60 monthsDescription: Measured via Duplex Ultrasound showing target vein closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual target vein after surgical stripping procedures.
Measure: Anatomic closure of target vein Time: 30 days, and 6, 12, 24, 36, 48 and 60 monthsDescription: Measured via Duplex Ultrasound showing target vein (including primary target vein) closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual target vein after surgical stripping procedures.
Measure: Technical success of each target vein Time: Index procedureDescription: Assessed via number of the target veins requiring retreatment.
Measure: Reintervention of any target vein Time: Index procedure through 60 monthsDescription: Adverse events occurring in target limb, evaluated from index procedure through 12 months are hypersensitivity to VenaSeal™ adhesive, phlebitis, granuloma, endovenous glue induced thrombosis (EGIT) or endovenous heat induced thrombosis (EHIT), symptomatic deep vein thrombosis (DVT) events.
Measure: Adverse events (AEs) occurring in the target limb Time: Index procedure through 12 monthsDescription: Additional adverse events that will be evaluated through 60 months are symptomatic pulmonary embolism (PE) and serious adverse events (SAEs).
Measure: Additional adverse events Time: Index procedure through 60 monthsDescription: Determined by using numeric rating scale (NRS) with a scale of 0-10, with '0' indicating no pain and '10' indicating worst pain imaginable.
Measure: Intra-procedural and post-procedural pain Time: Index procedure, and 7 days and 30 daysDescription: rVCSS score ranges from 0 to 30, with higher score indicating severe venous disease.
Measure: Change in venous disease symptoms compared to baseline measured by the revised Venous Clinical Severity Score (rVCSS) Time: 7 and 30 days, and at 6, 12, 24, 36, 48, and 60 monthsDescription: The total score ranges from 0-100 points, with '0' point indicating the best quality of life and '100' points indicating worst quality of life.
Measure: Change in Aberdeen Varicose Vein Questionnaire (AVVQ) score compared to baseline Time: 30 days, and 6, 12, 24, 36, 48, and 60 monthsDescription: Items are scored on a 1-5 scale, 5 being a worse outcome. Each of the 5 dimensions are scored separately to obtain a 5-digit code which is converted into a standard value by country. Max & min values vary by country.
Measure: Change in EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D-5L) compared to baseline Time: 30 days, and 6, 12, 24, 36, 48 and 60 monthsDescription: The total score ranges from 0 to 100, with higher scores indicating better general health perception.
Measure: Change in the 36-Item Short Form Health Survey (SF-36) compared to baseline Time: 30 days, and 6 and 12 monthsDescription: Measured by 0-5 and 0-7 point (there are two scales in this questionnaire) Likert scale with higher score indicating worst outcome.
Measure: Change in the Venous Dependent Quality of Life (VenousDQoL) compared to baseline Time: 30 days, and 6, 12, 24, 36, 48, and 60 monthsDescription: Measured by a 5 point Likert scale ranging from 0-5, with 5 indicating the best outcome (extremely satisfied with the treatment).
Measure: Provider experience evaluating overall satisfaction with the procedure Time: Index procedureDescription: Peri-procedural patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQe).
Measure: For VLU Study: Venous treatment satisfaction questionnaire-early (VenousTSQe) Time: 30 daysDescription: Patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQs).
Measure: For VLU Study: Venous treatment satisfaction questionnaire- status (VenousTSQs) Time: 30 daysDescription: Elimination of clinically relevant superficial truncal disease in each target vein at the time of index procedure as measured by the percentage of target vein length successfully treated.
Measure: For VLU Study: Percentage of target vein treated Time: Index procedureAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports